4-[3-(5-溴-2-丙氧基苯基)-5-(4-氯苯基)-1H-吡咯-2-基]吡啶 | 191034-25-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 4-[3-(5-溴-2-丙氧基苯基)-5-(4-氯苯基)-1H-吡咯-2-基]吡啶
• 英文名称: 4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]pyridine
• CAS: 191034-25-0
• 化学式: C₂₄H₂₀BrClN₂O
• 分子量: 467.8
• InChiKey: HHBOWXZOLYQFNY-UHFFFAOYSA-N

物化性质

• 沸点：
  542.3±50.0 °C(Predicted)
• 密度：
  1.367±0.06 g/cm3(Predicted)
• 溶解度：
  在 DMSO 中溶解度为 100 mM，在乙醇中溶解度为 100 mM

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] METHOD OF IDENTIFYING A COMPOUND THAT CHANGES THE AMYLOID-BETA PRECURSOR PROTEIN PROCESSING IN A CELL<br/>[FR] PROCEDE POUR IDENTIFIER UN COMPOSE QUI MODIFIE LE TRAITEMENT D'UNE PROTEINE PRECURSEUR DE LA BETA-AMYLOIDE DANS UNE CELLULE
  申请人：GALAPAGOS GENOMICS NV

  公开号：WO2005024057A1

  公开（公告）日：2005-03-17

  The present invention relates to methods of identifying a compound that changes the amyloid-beta precursor protein processing in a cell. The invention also relates to methods for changing the amyloid-beta precursor protein processing of a cell, and a method for diagnosing a pathological condition involving cognitive impairment or susceptibility to this condition in a subject.
• [EN] COMPOUNDS FOR THE TREATMENT OF DISEASES INVOLVING COGNITIVE IMPAIRMENT, SUCH AS ALZHEIMER'S DISEASE, AND METHODS FOR IDENTIFYING SUCH COMPOUNDS<br/>[FR] COMPOSES DESTINES AU TRAITEMENT DE MALADIES PROVOQUANT UN TROUBLE COGNITIF, TELLES QUE LA MALADIE D'ALZHEIMER ET METHODES PERMETTANT D'IDENTIFIER CES COMPOSES
  申请人：GALAPAGOS GENOMICS NV

  公开号：WO2005024058A2

  公开（公告）日：2005-03-17

  The present invention relates to compounds for use as a medicament in diseases involving cognitive impairment such as Alzheimer’s disease. In particular, the present invention relates to antagonists of and translation inhibitory compounds of the gene encoding FPRL1, FPRL2, FPR1, GPR32, CMKLR1, C5R1, GPR44, GCGR, GLP1R, GLP2R, GIPR, VIPR1, SCTR, VIPR2, providing a reduction of the levels of amyloid-beta protein. The invention further relates to methods for identifying such agonists and translation inhibitory compounds and methods for diagnosing a pathological condition involving cognitive impairment.